Journal
CANCER CELL INTERNATIONAL
Volume 23, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s12935-023-03004-7
Keywords
Long non-coding RNAs; Gemcitabine; Chemo resistance; Prognosis; Non-invasive marker; Cancer
Categories
Ask authors/readers for more resources
Chemotherapy is commonly used as a first-line therapy for cancer patients, but drug resistance poses a significant challenge. Long non-coding RNAs (lncRNAs) have been found to play a crucial role in regulating cellular processes associated with drug resistance. This review discusses the molecular mechanisms by which lncRNAs regulate the response to the nucleoside analog gemcitabine (GEM) in cancer patients. LncRNAs are reported to have an oncogenic role in inducing GEM resistance through various pathways, suggesting their potential as non-invasive markers to predict GEM response in patients.
Chemotherapy is widely used as one of the first line therapeutic methods in cancer patients. However, chemotherapeutic resistance is one of the most common problems in cancer patients, which leads to the therapeutic failure and tumor relapse. Considering the side effects of chemotherapy drugs in normal tissues, it is required to investigate the molecular mechanisms involved in drug resistance to improve the therapeutic strategies in cancer patients. Long non-coding RNAs (lncRNAs) have pivotal roles in regulation of cellular processes associated with drug resistance. LncRNAs deregulations have been frequently reported in a wide range of chemo-resistant tumors. Gemcitabine (GEM) as a nucleoside analog has a wide therapeutic application in different cancers. However, GEM resistance is considered as a therapeutic challenge. Considering the role of lncRNAs in the occurrence of GEM resistance, in the present review we discussed the molecular mechanisms of lncRNAs in regulation of GEM response among cancer patients. It has been reported that lncRNAs have mainly an oncogenic role as the inducers of GEM resistance through direct or indirect regulation of transcription factors, autophagy, polycomb complex, and signaling pathways such as PI3K/AKT, MAPK, WNT, JAK/STAT, and TGF-& beta;. This review paves the way to present the lncRNAs as non-invasive markers to predict GEM response in cancer patients. Therefore, lncRNAs can be introduced as the efficient markers to reduce the possible chemotherapeutic side effects in GEM resistant cancer patients and define a suitable therapeutic strategy among these patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available